CN103271939B - Anti-adhesion flushing fluid for operation - Google Patents
Anti-adhesion flushing fluid for operation Download PDFInfo
- Publication number
- CN103271939B CN103271939B CN201310239823.5A CN201310239823A CN103271939B CN 103271939 B CN103271939 B CN 103271939B CN 201310239823 A CN201310239823 A CN 201310239823A CN 103271939 B CN103271939 B CN 103271939B
- Authority
- CN
- China
- Prior art keywords
- methyl
- tetrahydrochysene
- adhesion
- hydroxyl
- pyrimidine carboxylic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses operation flushing fluid and particularly relates to an anti-adhesion flushing fluid for preventing operation adhesion. The anti-adhesion flushing fluid mainly comprises 1,4,5,6-tetralin-2-methyl-4-pyrimidine carboxylic acid, sodium chloride and water for injection. In the anti-adhesion flushing fluid for an operation, concentration of 1,4,5,6-tetralin-2-methyl-4-pyrimidine carboxylic acid is 0.1 to 40 g/L and concentration of sodium chloride is 1 to 50 g/L. The operation flushing fluid disclosed by the invention also can be added with a pH buffer. The inventor of the invention makes a series of animal experiments and researches to show that the human operation flushing fluid disclosed by the invention has an excellent operation cleaning effect and also has an excellent effect of preventing postoperative adhesion.
Description
Technical field
The present invention relates to a kind of surgical flush fluid, particularly a kind of surgical flush fluid that prevents surgical adhesions.
Background technology
Normal structure is suffering various damages to cause that, after inflammatory exudate, the situation such as hemorrhage, abnormal adhesion can occur adjacent separation tissue, makes injury limitation of activity or causes dysfunction in various degree.Implement after the surgical operation at the positions such as abdominal cavity, cardiovascular, spinal column, joint and tendon, conventionally can operation property adhesion problems.(Liakakos T according to the literature; Thomakos N; Fine PM; Dervenis C; Young RL. Peritoneal adhesions:etiology; pathophysiology, and clinical significance. Recent advances in prevention and management. Digestive Surgery. 2001; 18 (4): 260-273; Menzies D, Ellis H. Intestinal obstruction from adhesions--how big is the problem? Annals of The Royal College of Surgeons of England. 1990; 72 (1): 60-63.), after abdomen, operation on pelvis, tissue adhesion's incidence rate is about in 90%, 50% case, and intestinal and omentum majus are involved in adhesion meeting, cause thus many complication, as intestinal obstruction, chronic abdominal pain, Abdominal or pelvic adhesion etc.Tissue adhesion not only can affect surgical effect, causes serious post-operative complication, even can cause operative failure, as infertility that also can women etc.Therefore, operation property adhesion problems is thorny problem common in surgical operation always.
In recent years, researcher has carried out great many of experiments and clinical research, taked several different methods and measure to prevent tissue adhesion, as improve surgical technic, application machine barrier or solution barrier serosal surface isolation, use fibrinolysis thing or anticoagulation medicine etc. are disturbed to fiber formation, combination of Chinese and Western medicine tissue adhesion etc., but effect is all undesirable, and there is certain side effect.Clinical conventional surgical flush fluid, as mannitol flushing liquor, glycine flushing liquor and normal saline flushing liquid, have certain effect, but the effect of prevention of postoperative adhesion is still undesirable at aspects such as cleaning operative site, raising surgical field of view definition at present.Still lack and both there is the operation cleanout fluid that good operation cleaning action has good prevention of postoperative adhesion effect simultaneously clinically.
Summary of the invention
For above-mentioned prior art, the object of this invention is to provide a kind of operation cleanout fluid, especially a kind of operation cleanout fluid with prevention of postoperative adhesion effect.
The present invention is achieved by the following technical solutions:
A kind of operation anti-sticking flush fluid, mainly by 1,4,5,6-tetrahydrochysene-2-methyl-4-pyrimidine carboxylic, sodium chloride and water for injection form, and described operation is with in anti-sticking flush fluid 1,4, the concentration of 5,6-tetrahydrochysene-2-methyl-4-pyrimidine carboxylic is 0.1～40 g/L, and described operation is 1～50 g/L by the concentration of sodium chloride in anti-sticking flush fluid.
Described operation is 0.2～15 g/L by the concentration of (S)-2-methyl-1,4,5,6-tetra-hydro pyrimidine-4-carboxylic acid in anti-sticking flush fluid, and described operation is 1～10 g/L by the concentration of sodium chloride in anti-sticking flush fluid.
Described operation also contains pH buffer agent with anti-sticking flush fluid.
Described pH buffer agent is comprised of sodium hydrogen phosphate and sodium dihydrogen phosphate, and described operation is 0.2 mol/L by mole total concentration of sodium hydrogen phosphate in anti-sticking flush fluid and sodium dihydrogen phosphate.
The present inventor is carrying out 1,4, when 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic and derivant related experiment thereof, be surprised to find that, containing 1, the operation cleanout fluid of 4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic has good operation cleaning action, and can improve operative site definition, effectively the generation of prevention of postoperative adhesion.
The specific embodiment
Below in conjunction with embodiment, the present invention is further explained.Should be understood that, following examples are only for explaining the present invention, rather than limit the scope of the invention.
Embodiment 1 is containing Isosorbide-5-Nitrae, the preparation of the operation cleanout fluid of 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic
Fill a prescription as follows:
Isosorbide-5-Nitrae, 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic 0.5g
Sodium chloride 3g
Water for injection 1000ml
Preparation method is as follows:
Take recipe quantity sodium chloride and Isosorbide-5-Nitrae, 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic, add in 1000 ml waters for injection, stirring and dissolving, moist heat sterilization at 121 ℃, both must be containing 1, the operation cleanout fluid of 4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic.
Embodiment 2 is containing Isosorbide-5-Nitrae, the preparation of the operation cleanout fluid of 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic
Fill a prescription as follows:
Isosorbide-5-Nitrae, 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic 10g
Sodium chloride 8g
Water for injection 1000ml
Preparation method is as follows:
Take recipe quantity sodium chloride and Isosorbide-5-Nitrae, 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic, add in 1000 ml waters for injection, stirring and dissolving, moist heat sterilization at 121 ℃, both must be containing 1, the operation cleanout fluid of 4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic.
Embodiment 3 is containing Isosorbide-5-Nitrae, the preparation of the operation cleanout fluid of 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic
Fill a prescription as follows:
Isosorbide-5-Nitrae, 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic 35g
Sodium chloride 42g
Water for injection 1000ml
Preparation method is as follows:
Take recipe quantity sodium chloride and Isosorbide-5-Nitrae, 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic, add in 1000 ml waters for injection, stirring and dissolving, moist heat sterilization at 121 ℃, both must be containing 1, the operation cleanout fluid of 4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic.
Embodiment 4 is containing Isosorbide-5-Nitrae, the preparation of the operation cleanout fluid of 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic
Fill a prescription as follows:
Isosorbide-5-Nitrae, 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic 24g
Sodium chloride 30g
Water for injection 1000ml
Preparation method is as follows:
Take recipe quantity sodium chloride and Isosorbide-5-Nitrae, 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic, add in 1000 ml waters for injection, stirring and dissolving, moist heat sterilization at 121 ℃, both must be containing 1, the operation cleanout fluid of 4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic.
Embodiment 4 is containing Isosorbide-5-Nitrae, the preparation of the operation cleanout fluid of 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic
Fill a prescription as follows:
Isosorbide-5-Nitrae, 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic 24g
Sodium chloride 24g
Water for injection 1000ml
Preparation method is as follows:
Take recipe quantity sodium chloride and Isosorbide-5-Nitrae, 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic, add in 1000 ml waters for injection, stirring and dissolving, moist heat sterilization at 121 ℃, both must be containing 1, the operation cleanout fluid of 4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic.
Embodiment 5 is containing Isosorbide-5-Nitrae, the preparation of the operation cleanout fluid of 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic
Fill a prescription as follows:
Isosorbide-5-Nitrae, 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic 12g
Sodium chloride 5g
Water for injection 1000ml
Preparation method is as follows:
Take recipe quantity sodium chloride and Isosorbide-5-Nitrae, 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic, add in 1000 ml waters for injection, stirring and dissolving, moist heat sterilization at 121 ℃, both must be containing 1, the operation cleanout fluid of 4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic.
Embodiment 6 is containing Isosorbide-5-Nitrae, the preparation of the operation cleanout fluid of 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic
Fill a prescription as follows:
Isosorbide-5-Nitrae, 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic 12g
Sodium chloride 5g
Sodium hydrogen phosphate 0.162 mol
Sodium dihydrogen phosphate 0.038 mol
Water for injection 1000ml
Preparation method is as follows:
Take recipe quantity sodium hydrogen phosphate and sodium dihydrogen phosphate, add in 1000 ml waters for injection stirring and dissolving, microporous filter membrane under aseptic condition (aperture 0.45 μ m) filters, and degerming, except thermal source, then adds the sodium chloride and 1 of recipe quantity, 4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic, stirring and dissolving, moist heat sterilization at 121 ℃, both must contain Isosorbide-5-Nitrae, the operation cleanout fluid of 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic.
Embodiment 7 is containing Isosorbide-5-Nitrae, the preparation of the operation cleanout fluid of 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic
Fill a prescription as follows:
Isosorbide-5-Nitrae, 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic 10g
Sodium chloride 5g
Mannitol 5g
Water for injection 1000ml
Preparation method is as follows:
Take recipe quantity Isosorbide-5-Nitrae, 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic, sodium chloride and mannitol, add in 1000 ml waters for injection, stirring and dissolving, moist heat sterilization at 121 ℃, both must be containing 1, the operation cleanout fluid of 4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic.
Embodiment 8 is containing the anti pharmacodynamic experiment of operation cleanout fluid
60 of male SD rats, are divided into 6 groups every group 10 rats at random.File method is set up postoperative abdominal adhesions model: animal fasting is after 12 hours, use 10% chloral hydrate anesthesia, after cropping, sterilization, under sterile working, get front median incision 1.5 cm and enter abdomen, at ileocecus right flank, with key files, repeatedly rub placenta percreta to surperficial tip-like petechia, form approximately 4 cm
2after impaired wound surface, after air exposure 5 min, include abdominal cavity in, successively close abdominal cavity.
A group rat is model group, and postoperative normal raising, is not used any medicine; The positive matched group of B group rat, in complete the closing before abdominal cavity of operation, rinses wound surface with 10ml normal saline solution; C group is administration group, in complete the closing before abdominal cavity of operation, with the flushing liquor of 10ml embodiment 1 preparation, rinses wound surface; D group is administration group, in complete the closing before abdominal cavity of operation, with the flushing liquor of 10ml embodiment 4 preparations, rinses wound surface; E group is administration group, in complete the closing before abdominal cavity of operation, with the flushing liquor of 10ml embodiment 6 preparations, rinses wound surface; F group is administration group, in complete the closing before abdominal cavity of operation, with the flushing liquor of 10ml embodiment 7 preparations, rinses wound surface.
Within postoperative the 14th day, adopt cervical vertebra dislocation method to put to death animal, adopt cervical vertebra dislocation method to put to death, xiphoid-process lower cut enters abdomen, by 1 have neither part nor lot in operator according to Phillips grade scale, observe adhesion situation, record respectively adhesion score.Phillips grade scale is as follows: 0 grade: without being adhered, the reparation of caecum serosal surface is good completely; I level: caecum and surrounding tissue are adhered on a small quantity, loose easily separated, without oozing of blood; II level: caecum and surrounding tissue are gently adhered to moderate, intestinal tube can be " U " shape, and when separated, there is oozing of blood part; III level: intestinal tube and surrounding tissue are extensively adhered, more difficult separation, without intestinal obstruction; IV level: intestinal tube and surrounding tissue are closely adhered agglomerating, separation difficulty, causes incomplete or complete intestinal obstruction.The peritoneal adhesion scoring statistical result in postoperative the 14th day of SD rat is shown in 1.
Experimental result shows, contains Isosorbide-5-Nitrae, and the effect of the operation cleanout fluid prevention postoperative intestinal adhesion of 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic is better than clinical conventional normal saline flushing liquid at present.
Claims (3)
1. an operation anti-sticking flush fluid, it is characterized in that: by 1,4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic, sodium chloride, water for injection and pH buffer agent form, and described operation is with in anti-sticking flush fluid 1,4, the concentration of 5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic is 0.1～40 g/L, and described operation is 1～50 g/L by the concentration of sodium chloride in anti-sticking flush fluid.
2. operation anti-sticking flush fluid according to claim 1, it is characterized in that: described operation is with in anti-sticking flush fluid 1,4,5, the concentration of 6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic is 0.2～15 g/L, and described operation is 1～10 g/L by the concentration of sodium chloride in anti-sticking flush fluid.
3. operation anti-sticking flush fluid according to claim 1 and 2, it is characterized in that: described pH buffer agent is comprised of sodium hydrogen phosphate and sodium dihydrogen phosphate, described operation is 0.2 mol/L by mole total concentration of sodium hydrogen phosphate in anti-sticking flush fluid and sodium dihydrogen phosphate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310239823.5A CN103271939B (en) | 2013-06-17 | 2013-06-17 | Anti-adhesion flushing fluid for operation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310239823.5A CN103271939B (en) | 2013-06-17 | 2013-06-17 | Anti-adhesion flushing fluid for operation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103271939A CN103271939A (en) | 2013-09-04 |
| CN103271939B true CN103271939B (en) | 2014-10-08 |
Family
ID=49054187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310239823.5A Active CN103271939B (en) | 2013-06-17 | 2013-06-17 | Anti-adhesion flushing fluid for operation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103271939B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104055776A (en) * | 2014-06-26 | 2014-09-24 | 济南环肽医药科技有限公司 | Medical irrigating fluid |
| CN107753509A (en) * | 2016-08-19 | 2018-03-06 | 华仁药业股份有限公司 | A kind of electrolyte solution for surgery washing and preparation method thereof |
| CN106361764A (en) * | 2016-08-29 | 2017-02-01 | 沂水县人民医院 | Liver cancer surgical incision flushing liquid |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101366723A (en) * | 2007-08-16 | 2009-02-18 | 侯骏骥 | Medicinal composition |
| CN102225066A (en) * | 2011-04-29 | 2011-10-26 | 济南环肽医药科技有限公司 | Application of ectoine and its derivative in preparation of drug for treating pancreatitis |
| CN102225067A (en) * | 2011-04-29 | 2011-10-26 | 济南环肽医药科技有限公司 | Pharmaceutical composition for treating stomach cancer |
-
2013
- 2013-06-17 CN CN201310239823.5A patent/CN103271939B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101366723A (en) * | 2007-08-16 | 2009-02-18 | 侯骏骥 | Medicinal composition |
| CN102225066A (en) * | 2011-04-29 | 2011-10-26 | 济南环肽医药科技有限公司 | Application of ectoine and its derivative in preparation of drug for treating pancreatitis |
| CN102225067A (en) * | 2011-04-29 | 2011-10-26 | 济南环肽医药科技有限公司 | Pharmaceutical composition for treating stomach cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103271939A (en) | 2013-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105979891B (en) | Fluid management system and method | |
| CN103251987B (en) | Acellular biological patch, preparation method and apparatus thereof | |
| CN101693122B (en) | Method for preparing high molecular degradable skin dressing and application | |
| CN103271939B (en) | Anti-adhesion flushing fluid for operation | |
| CN105030667A (en) | Operation irrigating solution and preparation method thereof | |
| Ho et al. | Scrotal mass: a rare complication of ventriculoperitoneal shunt | |
| EP1001781A2 (en) | Use of taurolidine or taurultam for the manufacture of a medicament for the prevention of metastases | |
| CN102716073A (en) | Medical carboxymethyl chitosan anti-adhesion agent and preparation method thereof | |
| CN106176805A (en) | A kind of gynecilogical operation anti-sticking flush fluid and preparation method thereof | |
| JP5342695B2 (en) | Injectable composition for local administration for hemorrhoid treatment containing hydroxychloroquine | |
| RU2378997C1 (en) | Method of endoscopic maxillary sinusotomy | |
| Shah et al. | Laparoscopic excision of a congenital seminal vesicle cyst associated with ipsilateral renal agenesis | |
| CN105581822A (en) | CIT multi-endoscope combined stone extraction techniques with gallbladder preserved | |
| CN102755663A (en) | Formula of medical biocolloid solution and preparation method thereof | |
| Clark et al. | Staged suspension of an enteroatmospheric fistula: a novel surgical approach | |
| BR112013029616A2 (en) | "compounds for the treatment and prevention of adhesion, pharmaceutical compositions related to the compound and methods for the prevention and treatment of adhesions" | |
| RU2375066C2 (en) | Method for prevention of early postoperative thromboembolic complications | |
| Hernández et al. | Scrotal abscess secondary to appendicits. A case report | |
| Ngim et al. | Acute intestinal obstruction from postoperative adhesions in a tertiary health facility, South-South, Nigeria: A one year prospective study | |
| RU2467710C1 (en) | Method for reimplantation of spleen tissues | |
| CN108066343A (en) | A kind of drug prevented or treat kidney fibrosis disease | |
| WO1986000622A1 (en) | Hexapeptide | |
| US20220047687A1 (en) | Chemical scalpel | |
| RU2339368C1 (en) | Method for treatment of extensive peritonitis | |
| RU2676696C1 (en) | Method of pharmacological protection of kidney tissue during laparoscopic kidney resection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190910 Address after: 262515 No. 3787 New York Road, Qingzhou Economic Development Zone, Weifang City, Shandong Province Patentee after: Qingzhou Yaowang Pharmaceutical Co., Ltd. Address before: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 Patentee before: Jinan Huantai Pharmaceutical Technology Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200706 Address after: No.3787 wangmugong street, Qingzhou Economic Development Zone, Weifang City, Shandong Province Patentee after: Shandong Yizhou Biotechnology Co., Ltd Address before: 262515 No. 3787 New York Road, Qingzhou Economic Development Zone, Weifang City, Shandong Province Patentee before: QINGZHOU YAOWANG PHARMACEUTICAL Co.,Ltd. |